Pure Global
NCT06236256

Advanced Hybrid Closed Loop System (AHCL) in Older Patients With Type 1 Diabetes Mellitus

Advanced Hybrid Closed Loop System (780G) for People With Type 1 Diabetes Mellitus Patients Over the Age of 60: Efficacy in Improving Glucose Indices, Quality of Life, Cognitive Functions and Physical Capacity
Sheba Medical Center·ClinicalTrials.gov·device·Device trialRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Diabetes Mellitus, Type 1
Drug/Device/Intervention
MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Sheba Medical Center
Location
Ramat-Gan, Israel
Timeline & enrollment
Phase
N/A
Start date
Jan 09, 2024
End date
Sep 15, 2025
Enrollment
40 participants
Primary outcome

Improvement of glucose measures in older individuals

Summary

The trial is a randomized controlled, parallel group design study. Patients will be followed
 up during approximatively 12 months.
 
 Patients will be randomized to either the MDI/CSII group which will continue their treatment
 as per routine procedures and the advanced Hybrid Closed Loop system (AHCL) group which will
 be connected to the Minimed 780G system. .
 
 At the end of the 12 month study period, we will evaluate whether the AHCL system improved
 glucose indices in older individuals with Type 1 diabetes mellitus (T1DM) and assess whether
 the ACHL treatment improved physical capacity, frailty & sarcopenia indices as well as
 quality of life and cognitive functions.

ICD-10 classifications
Type 1 diabetes mellitusType 1 diabetes mellitus with unspecified complicationsType 1 diabetes mellitus with other specified complicationsType 1 diabetes mellitus without complicationsType 1 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06236256
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06236256 through Pure Global AI's free database. This phase not specified trial is sponsored by Sheba Medical Center and is currently Recruiting. The study focuses on Diabetes Mellitus, Type 1. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.